Eikon Therapeutics EIKN 深 滬
等待開盤 09-23 09:30:00 美东时间
8.98
+0.150
+1.70%
華盛通- 最 高9.33
- 今 開8.97
- 成交量 43.07万股
- 最 低 8.75
- 昨 收 8.83
- 總市值 48.64万
- 52周最高 17.40
- 市盈率 靜 --
- 換手率 0.80%
- 52周最低 7.90
- 委 比 -80.82%
- 總股本 5.42万
- 歷史最高 17.40
- 量 比 0.42
- 振 幅 6.57%
- 歷史最低 7.90
- 每 手 1
- 風險率 1.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Inhibrx, Eikon rise after insider buying
Shares of Inhibrx Biosciences (INBX) and Eikon Therapeutics (EIKN) traded higher on Wednesday as the cancer drug developers benefited from a series of insider purchases. Inhibrx (INBX) shares added mo...
09-10 00:21
Eikon Therapeutics to Participate in Investor Conferences in September 2026
Eikon Therapeutics announced that its CEO, Roger M. Perlmutter, and CFO, Freddie Bowie, will participate in two investor conferences in September: the 12th Annual Cantor Global Healthcare Conference on September 10 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. Both events will feature fireside chats and live webcasts available on Eikon’s investor relations website, with archives accessible for 30 days. Eikon is ...
08-26 11:30
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Wednesday. Shares of Estee Lauder Companies Inc (NYSE:EL) rose sharply after the company reported better-than-expected fourth-quarter financial results and issued its FY27 sales guidance with its midpoint above estimates. Ad...
08-19 22:08
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Eikon Therapeutics, Inc. GAAP EPS of -$1.63 misses by $0.03
Eikon Therapeutics, Inc. press release (EIKN): Q2 GAAP EPS of -$1.63 misses by $0.03. As of June 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $531.2 million. Eikon expects ...
08-14 04:59
Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial
Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following a prespecified analysis DMC recommended that the TeLuRide-006 study continue as p...
08-11 19:32
Eikon Therapeutics shares are trading higher. The company announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 study of EIK1001 with pembrolizumab and chemotherapy in stage 4 Non-Small Cell Lung Cancer.
Eikon Therapeutics shares are trading higher. The company announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 study of EIK1001 with pembrolizumab and chemotherapy in stage 4 Non-Small Cell Lung Cancer.
07-27 22:19
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
Eupraxia Pharmaceuticals Inc. announced updates to its executive leadership and operational structure to prepare for its next stage of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, bringing 25 years of experience in technical operations, CMC, and regulatory strategy. Dr. Alex Therien was appointed Executive Vice President, Research & Development, with over 20 years of biopharmaceut...
07-13 20:05
Eikon Therapeutics Set To Join Russell 3000 Index, Effective June
Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, ef...
06-26 04:15
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
